Back to search
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Autosomal Recessive Polycystic Kidney Disease (ARPKD) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Autosomal Recessive Polycystic Kidney Disease (ARPKD) trials you may qualify forCell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free…
To evaluate the safety of tolvaptan in pediatric subjects with ARPKD
Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a potentially lethal genetic disorder for which there are currently no disease specific treatments. Cli…
Hepato-renal fibrocystic diseases (HRFD) is a term developed that encompasses rare diseases such as Autosomal Recessive Polycystic Kidney Disease (ARPKD), and o…
polycystic kidney disease is aherditary disorder characterized by the formation of numerous fluid filled cysts in the kidneys which can lead to progressive rena…
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpo…
The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recess…
This study evaluates safety and tolerability of a single ascending dose of a tesevatinib liquid formulation administered to pediatric subjects with ARPKD.
This study will evaluate patients ciliopathies. People with ciliopathies develop fibrocystic disease of the kidneys and liver, retinal degeneration, obesity, st…